Market Place
Sourcing Support
Philly Jury Awards $250K vs. J&J in Baby Powder Trial
13 Feb 2026 //
BUSINESSWIRE
J&J`s Tremfya Roars Into 2026 With Massive January TV Ad Spend
11 Feb 2026 //
FIERCE PHARMA
Johnson & Johnson Joins Barclays Global Healthcare Conference
09 Feb 2026 //
BUSINESSWIRE
Abbvie CSO Highlights Breakthrough Psychedelic Therapy; J&J`s
06 Feb 2026 //
BIOSPACE
The Biggest Potential Drug Launches Of 2026
06 Feb 2026 //
FIERCE PHARMA
Johnson & Johnson Unveils OMNY-AF Pilot Study Results At 2026 AF
06 Feb 2026 //
BUSINESSWIRE
BMS, J&J Factor In HCP Education Before Milvexian Data Drop
03 Feb 2026 //
FIERCE PHARMA
Head-to-Head Analysis shows 51% reduction in Risk of Death
02 Feb 2026 //
PR NEWSWIRE
Johnson & Johnson at TD Cowen 46th Healthcare Conference
02 Feb 2026 //
BUSINESSWIRE
Johnson & Johnson receives CHMP positive opinion for AKEEGA
30 Jan 2026 //
GLOBENEWSWIRE
J&J’s Darzalex Faspro Notches Another Multiple Myeloma Indication
28 Jan 2026 //
PR NEWSWIRE
J&J`s $100M MedTech Donations Since 2020 Save Lives, Restore
27 Jan 2026 //
BUSINESSWIRE
Resolve M Therapeutics Exits From Stealth
22 Jan 2026 //
PHARMIWEB
J&J Targets $100B Sales, Overcomes Stelara Patent Cliff
22 Jan 2026 //
BIOSPACE
Expert Testimony Will Be Allowed In J&J Talc Litigation In N.J.
22 Jan 2026 //
FIERCE PHARMA
Johnson & Johnson Reports Q4 And Full-Year 2025 Results
21 Jan 2026 //
BUSINESSWIRE
Genmab Announces Net Sales Of DARZALEX (Daratumumab) For 2025
21 Jan 2026 //
GLOBENEWSWIRE
New Data Spotlights CAPLYTA For Remission in MDD Disorder
16 Jan 2026 //
PR NEWSWIRE
TECVAYLI Surpasses Standard of Care in R/R Multiple Myeloma
14 Jan 2026 //
PR NEWSWIRE
Johnson & Johnson Advances Depression Leadership With New Data
13 Jan 2026 //
PR NEWSWIRE
Johnson & Johnson Announces Multibillion Dollar Facility in NC
13 Jan 2026 //
CONTRACTPHARMA
Veristat Names Kim McLean Boericke as CEO
13 Jan 2026 //
CONTRACTPHARMA
RYBREVANT Shows Promising, Durable Responses in Colorectal Cancer
10 Jan 2026 //
PR NEWSWIRE
J&J Reveals US Drug Pricing Deal And Plans To Build 2 US Plants
09 Jan 2026 //
FIERCE PHARMA
Johnson & Johnson Enhances Medicine Access And Lowers Costs
09 Jan 2026 //
PHARMIWEB
Lexeo, J&J Team Up On Heart Pump Tech For Gene Therapy Delivery
08 Jan 2026 //
GLOBENEWSWIRE
J&J, Google Venture Arms Line Up To Back Epibiologics` Series B
08 Jan 2026 //
FIERCE BIOTECH
Lilly, J&J Top Clarivate`s 2026 Drugs to Watch
07 Jan 2026 //
FIERCE PHARMA
J&J Seeks FDA Clearance for OTTAVA Robotic Surgical System
07 Jan 2026 //
BUSINESSWIRE
Bayer Sues Moderna, J&J And Pfizer/Biontech Over COVID Vax Tech
07 Jan 2026 //
FIERCE PHARMA
J&J Submits EMA Application for TECVAYLI Combo in Myeloma
06 Jan 2026 //
GLOBENEWSWIRE
Johnson & Johnson Reveals Nipocalimab As First FcRn Blocker
06 Jan 2026 //
PR NEWSWIRE
J&J`s Tremfya Closes Out 2025 As December`s Top TV Ad Spender
06 Jan 2026 //
FIERCE PHARMA
Johnson & Johnson Declares Q1 2026 Dividend
02 Jan 2026 //
BUSINESSWIRE
Johnson & Johnson Completes Acquisition of Halda Therapeutics
29 Dec 2025 //
BUSINESSWIRE
J&J Halts Mid-stage Trial of Experimental Eczema Drug
27 Dec 2025 //
REUTERS
J&J vows appeal after US jury hits it with record $1.5B talc
27 Dec 2025 //
REUTERS
Europe Greenlights TREMFYA For Pediatric Plaque Psoriasis
19 Dec 2025 //
PHARMIWEB
Minnesota Jury Awards $65.5M vs. Johnson & Johnson
19 Dec 2025 //
BUSINESSWIRE
FDA Approves RYBREVANT + LAZCLUZE for Shortest First-Line Dosing
17 Dec 2025 //
PR NEWSWIRE
Janssen’s Biologics Rybrevant Faspro Receives Approval in US
17 Dec 2025 //
FDA
Link Cell Therapies Launches CAR-T for Solid, Liquid Tumors
15 Dec 2025 //
PR NEWSWIRE
Johnson & Johnson Hosts Investor Call On Q4 Results
15 Dec 2025 //
BUSINESSWIRE
FDA `Proactively` Awards J&J A National Priority Review Voucher
15 Dec 2025 //
FIERCE PHARMA
FDA Approves AKEEGA For BRCA2-Mutated Prostate Cancer
12 Dec 2025 //
PR NEWSWIRE
Majestec-3 Study Backs TECVAYLI With DARZALEX FASPRO
09 Dec 2025 //
PR NEWSWIRE
NHS Scotland Approves RYBREVANT for EGFR+ NSCLC
09 Dec 2025 //
PHARMIWEB
ASH: J&J Pressures CAR-T With Tecvayli Combo In 2L Myeloma
09 Dec 2025 //
FIERCE PHARMA
Carvykti Shows Durable Remissions in Relapsed Multiple Myeloma
06 Dec 2025 //
GLOBENEWSWIRE
Johnson & Johnson`s INLEXZO Shows 74% Disease-Free Survival
05 Dec 2025 //
PR NEWSWIRE
Eisai Stays Confident In Anti-Tau Asset Amid J&J Setback In Tau
05 Dec 2025 //
BIOSPACE
FDA Panel Votes Against J&J Shunt Implant For Heart Failure
05 Dec 2025 //
FIERCE BIOTECH
J&J Directs A New Campaign With Naomi Watts In The Spotlight
03 Dec 2025 //
FIERCE PHARMA
J&J Wins EU Approval for IMAAVY in Generalized Myasthenia Gravis
01 Dec 2025 //
GLOBENEWSWIRE
ASH25: J&J`s Tecvayli, Darzalex Data May Shift Myeloma Paradigm
25 Nov 2025 //
BIOSPACE
J&J`s Anti-Tau Antibody Posdinemab Flops In Phase 2
24 Nov 2025 //
FIERCE BIOTECH
J&J discontinues Alzheimer`s study of tau-targeting antibody
21 Nov 2025 //
PRESS RELEASE
Contineum-J&J drug fails to improve vision in ph. 2 MS trial
20 Nov 2025 //
BUSINESSWIRE
Merus, Halozyme Sign Global Pact to Develop Petosemtamab
17 Nov 2025 //
PR NEWSWIRE
New Long-Term Data Reinforces TREMFYA Blocking Joint Damage
17 Nov 2025 //
PR NEWSWIRE
